Study of afimkibart for moderate to severe ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ulcerative colitis (UC) and it is currently moderate to severe.
- You weigh at least 40 kilograms (about 88 pounds).
- You have tried at least one standard UC treatment (like a biologic or other advanced therapy) that didn't work, stopped working, or caused side effects.
- You do not have other serious bowel conditions like Crohn's disease, an ostomy pouch, or severe infections like tuberculosis or HIV.
- You are up to date with colon cancer screening (as per your local guidelines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called afimkibart in children with moderate to severe ulcerative colitis who haven't responded well to other treatments. It aims to see how well the drug works and if it's safe for children.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
This study looks at how afimkibart affects the way your body processes certain other medicines. It is for people with moderate to severe ulcerative colitis and helps researchers understand how to use this treatment safely.
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
Hear when a new Moderately to Severely Active Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.